-
Patritumab (INN) is a
human monoclonal antibody designed for the
treatment of cancer. It acts as an immunomodulator. It is in a
phase 2
clinical trial...
-
Patritumab deruxtecan (U3-1402/ MK-1022) is an
experimental antibody–drug
conjugate developed by
Merck and
Daiichi Sankyo to
treat non-small-cell lung...
- 2021. "
Patritumab Deruxtecan – U3-1402 – HER3 ADC". ADC Review.
Retrieved 17
December 2020. Seymour,
Caroline (30
January 2021). "
Patritumab Deruxtecan...
-
treatment of
breast cancer or
gastric or
gastroesophageal adenocarcinoma.
Patritumab deruxtecan, an
experimental antibody–drug
conjugate to
treat non-small-cell...
-
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding...
-
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding...
-
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding...
-
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding...
-
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies:
Duligotumab Patritumab Seribantumab ErbB4/HER4 Agonists:
Betacellulin Epigen Heparin-binding...
-
Necitumumab Nesva****ab§ Nivolumab#
Ofatumumab Olaratumab†
Panitumumab Patritumab§ Pembrolizumab# Pritumumab§ Radretumab§
Ramucirumab Rilotumumab† Robatumumab§...
